12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apriso granulated mesalamine: Phase III data

In a double-blind, U.S. Phase III trial in 305 patients with UC in remission, 1.5 g once-daily Apriso met the primary endpoint of a significantly higher proportion of relapse-free patients at 6 months vs. placebo (78.9% vs. 58.3%, p<0.001). Apriso also met the secondary endpoints of significantly improving SDAI scores for rectal bleeding (p=0.008), physician's rating...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >